Novo Nordisk's Strategic Countermoves Amid a Looming Patent Cliff

Novo Nordisk faces 2026 sales decline but eases EU Wegovy shipping rules and cuts US prices to fight rivals like Eli Lilly, as generic Ozempic looms.

Novo Nordisk shares, trading near €31.70, have shed roughly 29% since the start of the year, reflecting a challenging outlook for 2026. The Danish pharmaceutical giant anticipates a sales decline between 5 and 13 percent, pressured by expiring patents in key markets like India and China and intensifying global competition. This backdrop makes the company's recent operational maneuvers critical for defending its lucrative position in the weight-loss drug market.

In a significant regulatory shift, the European Medicines Agency (EMA) has relaxed cold-chain requirements for the injectable Wegovy formulation. The therapy can now be shipped at controlled temperatures for up to 48 hours, a move that substantially eases logistical complexity for EU distribution. This change eliminates the need for unbroken refrigeration from factory to patient, allowing pharmacies and online distributors to save on expensive specialty packaging. Management expects this to significantly boost the expansion of e-health and home-delivery services across the continent.

Across the Atlantic, Novo Nordisk is deploying an aggressive pricing strategy to combat rising competitive pressure. A new high-dose 7.2 mg version of Wegovy is now available in over 70,000 US pharmacies and select telehealth providers. For self-paying patients, the company has set a monthly price of approximately $399, undercutting comparable rival products by about $50. This pricing stands in stark contrast to its other blockbuster, Ozempic, which recently carried a monthly cost of nearly $1,000.

The competitive landscape is heating up on multiple fronts. Rival Eli Lilly is attacking the same target demographic with its once-daily oral GLP-1 drug, Foundayo (orforglipron), recently launched in the US. However, Novo Nordisk fired back with clinical data from the ORION trial, a head-to-head comparison. The results showed its own oral semaglutid (25 mg) achieved a mean weight loss 3.2 percentage points greater than Lilly's pill. Furthermore, patients discontinued treatment with orforglipron due to gastrointestinal side effects almost 14 times more frequently.

Adding to the long-term pressure, the US FDA has granted its first tentative approval for a generic version of Ozempic to Apotex Corp., developed with India's Orbicular Pharmaceutical Technologies. While the injectable semaglutid meets all FDA standards, it cannot be marketed until Novo Nordisk's US patents expire, which is expected no earlier than 2032. Upon launch, Apotex will receive 180 days of exclusive market access.

Despite the headwinds, Novo Nordisk maintains a substantial user base, with over 600,000 patients in the US already utilizing Wegovy products. The upcoming first-quarter results, scheduled for early May, will serve as a crucial litmus test. Investors will scrutinize the report to see if operational efficiencies from logistics savings and US growth can effectively offset the impact of declining list prices across the company's portfolio.